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Abstract
Background: It has been well documented that apolipoprotein M (apoM) is principally expressed in the liver and
kidney. However we found that there was weak apoM expression in other tissues or organs too, which could not
be ignored. In the present study, we therefore examined apoM expression in human colorectal tissues including
cancer tissues, cancer adjacent normal tissues, polyp tissues and normal mucosa as well as inflammatory mucosa.
Methods: Tissue samples were collected from patients who underwent surgical resection or endoscopic
examination. ApoM mRNA levels were determined by the real-time RT-PCR and apoM protein mass were examined
by the immunohistochemistry.
Results: ApoM protein can be detected in all colorectal tissues. However, apoM protein mass were significantly
lower in the cancer tissues than its matched adjacent normal tissues, polyp tissues, normal mucosa and
inflammatory mucosa. In parallel, apoM mRNA levels in the colorectal cancer tissues (0.0536 ± 0.0131) were also
significantly lower than those in their adjacent normal tissues (0.1907 ± 0.0563) (P = 0.033). Interestingly, apoM
mRNA levels in colorectal cancer tissues were statistic significant higher in the patients with lymph node metastasis
than the patients without lymph node metastasis (P = 0.008). Patients under Dukes’ C and D stages had much
higher apoM mRNA levels than patients under Dukes’ A and B stages (P = 0.034).
Conclusion: It is concluded that apoM could also be expressed in human colorectal tissues besides liver and
kidney. ApoM mRNA levels in the colorectal cancer tissues were significantly increased in the patients with lymph
node metastasis. Whether increased apoM expression in the patients with lymph node metastasis being related to
patients’ prognosis and the physiopathological importance of apoM expression in colorectal tissues need further
investigation.
Introduction
Apolipoprotein M (apoM) was first identified and char-
acterized in 1999 [1]. Human apoM gene is located in
the major histocompatibility complex (MHC) class III
locus on chromosome 6p21.31 (chromosome 17 in
mouse) and contains six exons [1]. It has been well
documented that human apoM is exclusively expressed
in the hepatocytes in liver and tubular epithelial cell in
kidney, and small amounts were also found in fetal liver
and fetal kidney in most investigations [2]. However, in
our previous study, during the human embryogenesis,
relative high apoM mRNA could also be found in small
intestine, stomach and skeletal muscle besides kidney
and liver in the early stages of embryogenesis [3]. More
recently, Calayir et al., reported that apoM could be
expressed in human colorectal adenocarcinoma cell line,
Caco-2 cells [4], which indicates that apoM might be
expressed in human colorectal tissues too. In the pre-
sent study we investigated whether apoM presented in
human colorectal tissues and further investigated the
difference of apoM expression pattern in colorectal
tissues from patients with colorectal cancer and benign
diseases.
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Materials and methods
Patients and samples
Both colorectal cancer tissues and their adjacent normal
tissues were collected from 20 patients (13 men and
7 women, aged from 38 to 82 years old, median age was
60 years old) who underwent surgical resection in the
hospital. All patients’ colon or rectal tumors were histo-
logically classified as the adenocarcinoma and none
patient had chemotherapy or radiotherapy before opera-
tion. Immediately after resection, small pieces of both
tumor and its adjacent normal tissues were collected
with snap-frozen and stored in liquid nitrogen before
further experiments. Parts of samples were fixed in 10%
(v/v) formalin and embedded in paraffin until use.
Twenty three colorectal biopsy samples (7 normal
mucosa, 6 inflammatory mucosa and 10 polyp tissues),
during endoscopic examinations, were collected for the
immunohistochemistry. The present study was approved
by the local ethics committee and all patients gave
informed consent.
Total RNA extraction and real-time RT-PCR
Total RNA in tissues was extracted according to the
manufacturer’s instructions by using a total RNA purifi-
cation kit (Biocolor BioScience and Technology Com-
pany, Shanghai, China). The quality of the RNA samples
was determined by the absorbance measurements at
260/280 nm. Using the first strand cDNA synthetic kit
(Fermantas, Vilnius, Lithuania) according to the manu-
facturer’s instructions, 2 μg total RNA was reverse tran-
scribed to cDNA. The mRNA levels of apoM and
GAPDH were measured under real-time RT PCR by
using TaqMan technology. The PCR primer sets were
designed to amplify the apoM and GAPDH gene
according to the information of GenBank, which are
listed in Table 1. The real-time PCR reaction for each
gene was performed in a 25 μL volume, in a glass capil-
lary, containing 0.1 μL 100 mM each primer and probe,
2 μL cDNA, 2.5 μL 10 × buffer, 1.5 μL MgCl2 (25 mM),
0.5 μL dNTP (10 mmol/L), and Taq DNA polymerase
0.5 μL. Thermal cycling conditions included following
steps: initial denaturation at 95°C for 2 min, followed by
40 cycles at 95°C for 5 sec and 60°C for 15 sec (apoM,
30 sec). All PCRs were performed on the LightCycler
(Roche, Switzerland) real-time PCR system. The pro-
spective amplicon of each gene was amplified and puri-
fied, then was ligated into the pMD19-T vector, and
then ligated product was transformed into the E. Coli
JM109 competent cells. In brief, a serial dilution of
extracted plasmid DNA was used to generate a standard
curve by plotting the cycle threshold versus the log
initial copy number of input plasmid DNA. Both apoM
and GAPDH standard curves achieved a very high-
correlation coefficient (= 1.00). The ratio between the
target gene and GAPDH was calculated to provide
relative gene expression.
Immunohistochemistry
Normal mucosa, inflammatory mucosa, polyp tissues and
both colorectal cancer tissues as well as their adjacent
normal tissues from all patients were cut into sections
under 3-μm thick for the immunohistochemical analyses.
In brief, formalin-fixed, paraffin wax embedded tissues
were dewaxed in xylene and rehydrated in graded ethanol
solutions. Antigen retrieval was performed by incubating
the slides at 100°C for 30 min in a 10 mmol/L citrate
buffer (pH 6.0). Slides were cooled and immersed in a
0.3% hydrogen peroxide solution for 15 min to block
endogenous peroxidase activity, and rinsed in PBS for
5 min, incubated with 5% bovine serum albumin at room
temperature for 15 min to eliminate non-specific binding
of primary antibody. Sections were then incubated with
primary monoclonal antibodies against apoM (1:50 dilu-
tions in PBS) (BD Biosciences) at 4°C overnight. PBS was
used as negative control instead of the primary antibody.
Then sections were incubated with HRP-labeled goat
anti-mouse/rabbit secondary antibody (Ready to use,
Maixin Biotechnology Limited Corporation, Fuzhou,
China) for 30 min at room temperature. Diaminobenzi-
dene (DAB) was used as the chromogen and hematoxylin
as the nuclear counterstain. The sections were dehy-
drated, cleared and mounted.
Evaluation of apoM immunohistochemical staining
Two pathologists were invited to examine the slides. In
brief, five high-power fields (×200) were randomly
selected. Intensity of apoM immunochemical staining
and percentage of positive cells were assessed. The
extent of the staining was categorized into five semi-
quantitative classes based on the percentage of positive
cells: 0 (< 5% positive cells), 1 (6-25% positive cells),
2 (26-50% positive cells), 3 (51-75% positive cells) and
4 (> 75% positive cells) [5]. The intensity of cytoplasmic
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and membrane staining was also semi-quantitatively
determined on a scale of 0-3 as follow: 0 (negative), 1
(weak positive), 2 (moderate positive) and 3 (strong
positive). Final staining score were obtained by multipli-
cation of the intensity and the percentage scores and
were represented as: 0 (negative), weak positive (1-4),
moderate positive (5-8) and strong positive (9-12) [6]. In
the present study we practically divided patients into
two groups: low apoM expression group (score 0-8) and
high apoM expression group (score 9-12).
Statistical analysis
Results are expressed as means ± SE. Data were ana-
lyzed with the GraphPad Prism 4.0 software package
(GraphPad Software, Inc., San Diego, California, USA).
The paired t test, c2-test and Mann Whitney test were
applied for the statistical analyses. A P value less than
0.05 was considered to be significant.
Results
Immunohistochemical staining of apoM in normal
mucosa, inflammatory mucosa, polyp tissues and cancer
tissues
As shown in the figures 1 and 2, apoM protein could be
detected in all colorectal tissues. However, apoM protein
mass in the colorectal cancer tissues were significantly
decreased compared to its adjacent tissues (Figure 1 and
Table 2). And apoM protein mass was also much lower
in the cancer tissues than those in the polyp tissues,
normal mucosa and inflammatory mucosa (Table 3).
ApoM mRNA level and protein concentration in cancer
tissue and its adjacent normal tissue
As shown in figure 3, apoM mRNA levels in colorectal
cancer tissues (0.0536 ± 0.0131) were significantly lower
than those in their adjacent normal tissues (0.1907 ±
0.0563) (P = 0.033). In parallel the apoM immunohisto-
chemical staining were also much weaker in the cancer
tissues than in their adjacent normal tissues (P < 0.0001,
Table 2 and Figure 1). Under immunochemical staining,
apoM protein was mainly located in normal columnar
epithelial cells of the colorectal mucosa (Figure 1B) and
non-regularly stained in the colorectal carcinoma cells
(Figure 1D).
Correlation of apoM mRNA levels and protein mass to
patients’ clinical characteristics
The present study clearly demonstrated that apoM
mRNA levels in colorectal cancer tissues were signifi-
cantly higher in the patients with lymph node metastasis
than in patients without lymph node metastasis (P =
0.008), whereas apoM protein mass had no such differ-
ence between these two group patients (Table 4). Com-
pared to patients under Dukes’ A and B stages, patients
Figure 1 Immunochemical staining of apoM in the colorectal tumor tissue and in its adjacent normal tissue. Panels A and C show HE
staining. Panels B and D show the immunohistochemical staining of apoM performed as described in material and methods. Brown color
indicates positive staining. Magnification ×200.
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under Dukes’ C and D stages had higher apoM mRNA
levels (P = 0.034), but not the apoM protein levels
(Table 4). Neither apoM mRNA levels nor apoM protein
concentrations in the colorectal cancer tissues were cor-
related to patients’ sex, age, tumor stage, tumor size and
tumor locations (Table 4).
Discussion
The tissue distribution, location of cellular expression,
structure feature [1-3,7,8], and potential roles [9-15] as
well as regulation of apoM [9,16-28] have been gradually
elucidated since it was found and initially identified
from human chylomicrons in 1999[1]. According to the
literature, apoM is exclusively expressed in the hepato-
cytes in liver and in the tubular epithelial cells in kidney
[2,3], and small amounts apoM expressed in the fetal
liver and kidney too [3]. More recently, Calayir et al.
reported that apoM expression could be up-regulated by
the LXR agonist in human colorectal adenocarcinoma
cell line, Caco-2 cells [4], which indicates that apoM
Figure 2 Immunochemical staining of apoM in normal mucosa, inflammatory mucosa, and polyp tissue. Panels A, C and E show HE
staining of normal mucosa, inflammatory mucosa, and polyp tissue, respectively. Panels B, D and F show intensity of apoM immunostaining in
the normal mucosa, inflammatory mucosa, and polyp tissue. Magnification ×200.
Table 2 Intensity of apoM immunochemical staining in the colorectal cancer tissues and their adjacent normal tissues
Colorectal cancer tissue Adjacent normal tissue Odds ratio P-value
Low apoM HIS (score: 0-8) 16 (80%) 3 (15%)
22.67 < 0.0001
High apoM HIS (score: 9-12) 4 (20%) 17 (85%)
IHS: immunohistochemical staining
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might be also expressed in human colorectal tissues.
However, our previous study [26] and Calayir’s report
demonstrated that LXR agonist could significantly inhi-
bit apoM expression in HepG2 cells [4], which indicates
that apoM in liver and in colon may have different phy-
siological functions. We have previously reported that
plasma apoM levels in the hepatocellular carcinoma
(HCC) patients were significantly increased than those
in the normal subjects [29]. However, both apoM
mRNA levels and apoM protein mass in the HCC
tissues were significantly lower than those in their adja-
cent tissues [30].
In the present study, we demonstrated that apoM was
abundantly expressed in normal colorectal tissues and
Table 3 Scores of apoM immunohistochemical staining in
different colorectal tissues
Tissues N Median Interquartile range P-value*
Normal mucosa 7 10.50 3 0.0109
Inflammatory mucosa 6 9.75 4.5 0.0356
Polyp tissues 10 11 3.75 0.0017
Cancer tissues 20 5.5 4
* The Mann Whitney test was applied, compared with cancer tissues.
Figure 3 ApoM mRNA levels in the colorectal tumor tissues
and in their adjacent normal tissues. The mRNA levels of apoM
and GAPDH were determined by the real-time RT-PCR. Data are
means ± SE (n = 20) and are analyzed with the paired student t
test. *P < 0.05 vs. Adjacent normal tissues.
Table 4 Correlation of apoM mRNA levels and protein levels with patients’ clinical characteristics
Characteristic n ApoM mRNA levels ApoM protein levels
Ratio of ApoM/GAPDH (Median) P-value* Staining score (Median) P-value*
Sex 1.000 0.250
Male 13 0.0289 5
Female 7 0.0386 7
Age 0.362 0.648
< 60 9 0.0386 4
≥ 60 11 0.0204 6
Tumor size (diameter) 0.403 0.211
< 6 cm 11 0.0386 4
≥ 6 cm 9 0.0204 6
Location 0.481 0.529
Colon 10 0.0338 6.5
Rectum 10 0.0271 4.5
Lymph node metastasis 0.008 0.790
without 9 0.0151 5
with 11 0.0514 6
Dukes’ stage 0.034 0.511
A+B 8 0.0172 5
C+D 12 0.0450 6
Tumor (T) stage† 0.337 0.694
pT1+ pT2 5 0.0193 6
pT3+ pT4 15 0.0305 5
* The Mann Whitney test was applied.
† The stage was determined by pathological (p) examination. T1: Tumor invading submucosa, T2: Tumor invading muscularis propria, T3: Tumor penetrating
muscularis propria and invading subserosa, and T4: Tumor invading other organs or structures or perforating visceral peritoneum.
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with inhibited levels found in the colorectal cancer tis-
sues. Interestingly, apoM mRNA levels were significantly
increased in the colorectal cancer tissues of patients
with lymph node metastasis than the patients without
lymph node metastasis. Moreover we demonstrated that
apoM mRNA levels were much higher in the patients
with Dukes’ stages 3 and 4 than the Dukes’ stages 1 and
2, which indicates that apoM mRNA levels in cancer tis-
sues may have a potential positive correlation to the
tumor progress, although apoM protein mass were not
parallel increased in the patients with lymph node
metastasis. This may suggest, although apoM expression
is obviously decreased in the colorectal cancer tissues
than in normal tissues, there are certain factors or
mechanism could up-regulate apoM expression during
the progress of the cancers. Perhaps apoM mRNA levels
in colorectal cancer tissues can be determined for evalu-
ating the metastasis, and further for patient’s prognosis.
Certainly it needs a standardized method for determin-
ing apoM mRNA level in the cancer tissues. In addition,
it is still need to elucidate weather production of apoM
in intestine influences plasma apoM pool in human.
Some proteins, such as alpha-fetoprotein (AFP), are
normally produced in the developing embryo and fetus
by hepatocytes, gastrointestinal cells and yolk sac cells.
Synthesis of AFP stops at birth and its increased level is
associated with pathological conditions [31]. In our pre-
vious study, apoM expression could also be found in
small intestine, stomach and skeletal muscle in the early
stages of embryogenesis [3]. We suspected whether
apoM expression in adult colorectal tissues was influ-
enced under cancer condition. In the present study, we
examined apoM expression in normal mucosa, inflam-
matory mucosa, polyp and cancer tissues, which shows
clearly that these tissues do express apoM, although
apoM expression in the cancer tissues were significantly
inhibited.
In conclusion, the present study revealed that apoM
could also be abundantly expressed in human colorectal
tissues, although the physiopathological importance of
this expression and if it could influence plasma apoM
pool are unknown yet. Moreover we demonstrated that
apoM mRNA levels were significantly increased in the
colorectal cancer tissues of patients with lymph node
metastasis, although apoM expression in cancer tissues
was generally much lower than in normal colorectal tis-
sues. Determination of apoM mRNA in the surgical
resected colorectal cancer tissues may have potential
benefit for evaluating patient’s prognosis.
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